Abstract
In This Issue...
Decision Resources, Inc., forecasts that the market for metabolic syndrome
therapies will increase from $9.7 billion in 2003 to $12.8 billion in 2013.
This market has enormous untapped potential, especially in Europe, but several
major barriers (e.g., a lack of consensus on the definition of the disease,
underdiagnosis, poor management, difficulties in the licensing of new
therapies, reimbursement restrictions) have constrained growth. In this
report, we consider the problems resulting from the lack of a consensus
definition of metabolic syndrome. We then examine how limited knowledge and
inadequate screening have contributed to underdiagnosis of the disease. We
review therapeutic options and assess the reimbursement environment for
metabolic syndrome therapeutics. Further, we analyze the challenges that face
drugs in development for this disorder and the consequences of a renewed
debate over the validity of metabolic syndrome as a distinct disease. We
conclude with an assessment of the outlook and implications for the
pharmaceutical industry.
View Cart
